Thus, combination therapy seems promising for cancer therapy (Sathyanarayanan and Neelapu, 2015), as immunotherapy targeting TIM3 appeared to be effective in combination with anti‐PD‐1 or anti‐CTLA‐4 (Hervas‐Stubbs et al., 2016; Ngiow et al., 2011b). The gene discussed is HAVCR2; the disease is cancer.